Heart Failure Quality of Care and In-hospital Outcomes During the COVID-19 Pandemic: Findings from the Get With The Guidelines-Heart Failure Registry
Overview
Authors
Affiliations
Aims: To assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic.
Methods And Results: Patients hospitalized for HF with ejection fraction (EF) <40% in the American Heart Association Get With The Guidelines©-HF (GWTG-HF) registry during the COVID-19 pandemic (3/1/2020-4/1/2021) and pre-pandemic (2/1/2019-2/29/2020) periods were included. Adherence to HF process of care measures, in-hospital mortality, and length of stay (LOS) were compared in pre-pandemic vs. pandemic periods and in patients with vs. without COVID-19. Overall, 42 004 pre-pandemic and 37 027 pandemic period patients (median age 68, 33% women, 58% White) were included without observed differences across clinical characteristics, comorbidities, vital signs, or EF. Utilization of guideline-directed medical therapy at discharge was comparable across both periods, with rates of implantable cardioverter defibrillator (ICD) placement or prescription lower during the pandemic (vs. pre-pandemic period). In-hospital mortality (3.0% vs. 2.5%, p <0.0001) and LOS (mean 5.7 vs. 5.4 days, p <0.0004) were higher during the pandemic vs. pre-pandemic. The highest in-hospital mortality during the pandemic was observed among patients hospitalized in the Northeast region (3.4%). Among patients concurrently diagnosed with COVID-19 (n = 549; 1.5%), adherence to ICD placement or prescription, prescription of aldosterone antagonist or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor at discharge were lower, and in-hospital mortality (8.2% vs. 3.0%, p <0.0001) and LOS (mean 7.7 vs. 5.7 days, p <0.0001) were higher than those without COVID-19.
Conclusion: Among GWTG-HF participating hospitals, patients hospitalized for HF with reduced EF during the pandemic received similar care quality but experienced higher in-hospital mortality than the pre-pandemic period.
Srivastava P, Klomhaus A, Greene S, Heidenreich P, Lewsey S, Yancy C JAMA Cardiol. 2024; 10(3):276-283.
PMID: 39661383 PMC: 11904728. DOI: 10.1001/jamacardio.2024.3815.
Cho D, Choi J, Youn J, Kim M, Lee C, Son J ESC Heart Fail. 2024; 12(1):603-612.
PMID: 39420468 PMC: 11769608. DOI: 10.1002/ehf2.15117.
Srivastava P, Klomhaus A, Rafique A, Desai P, Daniels L, Yancy C Am Heart J Plus. 2024; 45:100440.
PMID: 39220717 PMC: 11363726. DOI: 10.1016/j.ahjo.2024.100440.
Han L, Zhao S, Li S, Gu S, Deng X, Yang L Nat Cardiovasc Res. 2024; 2(3):322-333.
PMID: 39195997 DOI: 10.1038/s44161-023-00220-2.
Prioritizing the primary prevention of heart failure: Measuring, modifying and monitoring risk.
Patel R, Peesay T, Krishnan V, Wilcox J, Wilsbacher L, Khan S Prog Cardiovasc Dis. 2024; 82():2-14.
PMID: 38272339 PMC: 10947831. DOI: 10.1016/j.pcad.2024.01.001.